Scroll to top
Follow Us
–
Fb.
Tw.
Li.
Yt.
Inst.
Skip to content
About
Company
About CLINUVEL
Risk Management & ESG Statement
Mission, Vision & Values
History & Future
People
Board
Management
Corporate Governance
Pharmaceutical Technology
SCENESSE®
About Melanocortins
Published Research
Scientific Communiqués
Pipeline
Disease Entities
Erythropoietic Protoporphyria (EPP)
Variegate Porphyria (VP)
Vitiligo
DNA Repair
Xeroderma Pigmentosum (XP)
Arterial Ischaemic Stroke (AIS)
Healthcare Solutions
Investors
News
Latest News
Share Price
Announcements Calendar
CLINUVEL Online
CLINUVELNews
ASX Announcements
Company Snapshot
Financial Overview
Shareholder Information
Media Coverage
Analyst Coverage
Annual Reports
Enquiries
FAQ
© CLINUVEL PHARMACEUTICALS LTD 2023. All rights reserved. |
Sitemap
|
Disclaimer
|
Privacy Policy
To report
suspected adverse reactions
, contact CLINUVEL via
safety@clinuvel.com
or (US only) the FDA at 1-800-FDA-1088 or
www.fda.gov/medwatch.
Follow Us
–
Fb.
Tw.
Li.
Yt.
Inst.
Contact Us
Search for
Back
210303 Appendix 3Y
Home
Posted by
CLINUVEL
March 3, 2021
1 min read
210303 Appendix 3Y
Read More
Posted by
CLINUVEL
October 29, 2020
1 min read
Local XLSX
Read More
Posted by
CLINUVEL
October 29, 2020
1 min read
Local PPTX
Read More
Posted by
CLINUVEL
October 29, 2020
1 min read
Local DOCX
Read More
Posted by
CLINUVEL
October 29, 2020
1 min read
Local PDF
Read More
Posted by
CLINUVEL
October 29, 2020
1 min read
Google Drive PPT
Read More
Posted by
CLINUVEL
October 29, 2020
1 min read
Google Drive PPTX
Read More
Posted by
CLINUVEL
October 29, 2020
1 min read
Google Drive XLS
Read More
Posted by
CLINUVEL
October 29, 2020
1 min read
Google Drive XLSX
Read More
Posted by
CLINUVEL
October 29, 2020
1 min read
Google Drive - DOCX
Read More
Posted by
CLINUVEL
October 29, 2020
1 min read
Google Drive - DOC
Read More